Latest BioPharma News and In-Depth Analysis | BioPharma BoardRoom

06 October, 2026 | Tuesday

Vaxart Secures European Patent Protection for Oral Norovirus Vaccine Technology

Vaxart, Inc., a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, an...

August 28, 2026 | Friday | News

Partner Content

Seeing Biologics in Action: The Next Frontier in Analytical Science
17 September, 2026
Symbiosis Expands Sterile Manufacturing Capacity with £26m Investment
23 September, 2026
Scaling Biopharma Without Compromising Quality
17 September, 2026
Designing the Next Generation of Cell and Gene Therapies for Scale
17 September, 2026
Building Quality into the Future of Advanced Biopharma
17 September, 2026
Making Earlier Cancer Detection a Reality Through Blood-Based Diagnostics
09 September, 2026

BioPharma BreakThrough's

Nanochon Receives Panama Approval to Begin First-in-Human Chondrograft Knee Study
17 August, 2026
Everest Medicines Advances Local Manufacturing of VELSIPITY in China with Priority Review
05 October, 2026
SkinHealth Systems Expands SkinStylus Microneedling Device Across Six European Markets
02 October, 2026
Vanda Reports Positive Phase III Results for HETLIOZ in Delayed Sleep-Wake Phase Disorder
01 October, 2026
Egle Therapeutics Reports Phase 1 Data for Treg-Selective EGL-003 in Autoimmune Disease
01 October, 2026
Innovent Reports Phase 1 Data for IBI3003 Trispecific Antibody in Multiple Myeloma
30 September, 2026

Editor Picks

RefinedScience Expands Pancreatic Cancer Dataset With Multi-Institutional Sample Access
28 September, 2026
Firefly Neuroscience Partners With NeuroSigma to Expand Access to Monarch eTNS for Pediatric ADHD
28 September, 2026
ACROBiosystems Expands French Presence With New Hub at Kadans Science Partner’s The HIVE
25 September, 2026
Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer
25 September, 2026
Pharming Seeks FDA Approval to Expand Joenja Use to Younger Children With APDS
28 September, 2026
Daiichi Sankyo and Merck Withdraw U.S. BLA for Ifinatamab Deruxtecan in Small Cell Lung Cancer
28 September, 2026

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

Gene Editing Breakthroughs

Innovative Drug Discovery

Vaccine Development

Biologics and Therapeutic Antibodies

× Please select an option to participate in the poll.

View poll results More polls

× You have successfully cast your vote.

{{ optionDetail.option }} {{ optionDetail.percentage }}%

More polls

About Us Media Pack Contact Us Privacy Policy

© 2026 Biopharma Boardroom. All Rights Reserved.